The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...

Conclusions: Lack of phosphorylation of AKT and lack of PTEN expression in the AKT pathway downstream of EGFR may be a mechanism of MPM's clinical resistance to OSI-774. ERK is variably activated ...

The phosphoinositide-3 kinase (PI-3K)/AKT cell survival pathway is an important pathway activated by EGFR signaling. Here we show, that in addition to previously described critical components of this ...